Alkem Laboratories Ltd, a multinational pharmaceutical company, is set to acquire assets related to Active Pharmaceutical Ingredient (API) Dronabinol from United States-based AbbVie Inc. for a cash consideration of $10 million. The expected date of completion was set to be on or before 31 st December 2019. As per BSE filing, the company said, “This…